Sage Therapeutics (NASDAQ:SAGE) Given New $13.00 Price Target at Truist Financial

Sage Therapeutics (NASDAQ:SAGE) had its target price lowered by Truist Financial from $18.00 to $13.00 in a research report released on Wednesday, Benzinga reports. The firm currently has a hold rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also issued reports on SAGE. The Goldman Sachs Group dropped their price target on Sage Therapeutics from $19.00 to $11.00 and set a neutral rating on the stock in a research report on Friday, July 26th. Canaccord Genuity Group dropped their target price on shares of Sage Therapeutics from $21.00 to $17.00 and set a hold rating on the stock in a report on Friday, April 26th. Citigroup initiated coverage on shares of Sage Therapeutics in a report on Wednesday, May 29th. They issued a sell rating and a $8.00 price target for the company. Needham & Company LLC reiterated a hold rating on shares of Sage Therapeutics in a research note on Thursday, August 1st. Finally, TD Cowen cut shares of Sage Therapeutics from a buy rating to a hold rating and cut their target price for the stock from $16.00 to $10.00 in a report on Tuesday, July 30th. Two research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of Hold and an average target price of $16.06.

Sage Therapeutics Stock Up 1.4 %

Shares of SAGE traded up $0.11 during midday trading on Wednesday, hitting $8.13. The company had a trading volume of 35,797 shares, compared to its average volume of 1,083,208. Sage Therapeutics has a 52 week low of $7.70 and a 52 week high of $28.26. The company’s 50 day moving average price is $10.67 and its 200 day moving average price is $15.18. The stock has a market cap of $496.34 million, a price-to-earnings ratio of -0.95 and a beta of 0.90.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.02). Sage Therapeutics had a negative net margin of 458.30% and a negative return on equity of 55.87%. The firm had revenue of $8.65 million during the quarter, compared to the consensus estimate of $8.85 million. During the same period in the prior year, the firm earned ($2.68) earnings per share. The firm’s quarterly revenue was up 249.8% compared to the same quarter last year. Equities analysts anticipate that Sage Therapeutics will post -6.43 EPS for the current fiscal year.

Institutional Trading of Sage Therapeutics

Several hedge funds have recently added to or reduced their stakes in SAGE. Trexquant Investment LP acquired a new position in shares of Sage Therapeutics during the fourth quarter valued at $2,234,000. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of Sage Therapeutics by 1,049.2% in the 4th quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 201,107 shares of the biopharmaceutical company’s stock valued at $4,358,000 after acquiring an additional 183,607 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Sage Therapeutics by 69.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company’s stock valued at $15,217,000 after purchasing an additional 333,805 shares in the last quarter. Vanguard Group Inc. boosted its position in Sage Therapeutics by 8.1% during the 1st quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company’s stock worth $107,781,000 after acquiring an additional 432,013 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Sage Therapeutics by 1,058.4% during the first quarter. Assenagon Asset Management S.A. now owns 156,593 shares of the biopharmaceutical company’s stock worth $2,935,000 after purchasing an additional 143,075 shares during the period. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.